TMPYP4 exerted antitumor effects in human cervical cancer cells through activation of p38 mitogen-activated protein kinase
© The Author(s) 2017
Received: 13 March 2017
Accepted: 21 June 2017
Published: 3 July 2017
The aim of the present study was to investigate the potential effects of the 5,10,15,20-tetrakis (1-methylpyridinium-4-yl) porphyrin (TMPyP4) on the proliferation and apoptosis of human cervical cancer cells and the underlying mechanisms by which TMPyP4 exerted its actions.
After human cervical cancer cells were treated with different doses of TMPyP4, cell viability was determined by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) method, the apoptosis was observed by flow cytometry (FCM), and the expression of p38 mitogen-activated protein kinase (MAPK), phosphated p38 MAPK (p-p38 MAPK), capase-3, MAPKAPK2 (MK-2) and poly ADP-ribose polymerase (PARP) was measured by Western blot analysis. The analysis revealed that TMPyP4 potently suppressed cell viability and induced the apoptosis of human cervical cancer cells in a dose-dependent manner. In addition, the up-regulation of p-p38 MAPK expression levels was detected in TMPyP4-treated human cervical cancer cells. However, followed by the block of p38 MAPK signaling pathway using the inhibitor SB203580, the effects of TMPyP4 on proliferation and apoptosis of human cervical cancer cells were significantly changed.
It was indicated that TMPyP4-inhibited proliferation and -induced apoptosis in human cervical cancer cells was accompanied by activating the p38 MAPK signaling pathway. Taken together, our study demonstrates that TMPyP4 may represent a potential therapeutic method for the treatment of cervical carcinoma.
KeywordsTMPyP4 p38 MAPK Human cervical cancer cells Proliferation Apoptosis
Cervical cancer is the fourth common malignant tumor in women which leads to approximately 274,000 mortalities every year worldwide according to the reports of the World Health Organization (WHO) . Notably, 85% of cases and deaths occur in low- and middle-income countries . Human papillomavirus (HPV) types is recognized as an essential precursor to the development of cervical cancer. The WHO has recommended the routine HPV vaccination in national immunization programmes worldwide. Early stage cervical cancer may be treated by triggering tumor cell apoptosis through the combined application of radiotherapy and chemotherapy . However, patients with late-stage cervical cancer exhibit a poor physical condition, resulting in the limits of the application of radiotherapy, chemotherapy or the two therapies combined . Currently, the pathogenesis of cervical cancer has not yet been completely understood, and there are no drugs available for effectively controlling the occurrence and development of this cancer . So, it is urgent for us to seek new potential drugs and biomarkers for its diagnosis, prognosis, and therapy to improve clinical strategies of cervical cancer.
The cationic porphyrin, 5,10,15,20-tetra-(N-methyl-4-pyridyl) porphine (TMPyP4), a novel type of synthetic water-soluble photosensitizer, has been recently developed as a chemotherapeutics drug for treating cancers . It has been reported that TMPyP4 leads to the arrest of tumor cell growth, and induces the apoptosis of tumor cells through reducing the telomerase activity [7–9], indicating that TMPyP4 presents a potential therapeutic target in tumor cells. Therefore, it is crucial to comprehensively understand biological effects of TMPyP4 in tumor cells before it can be used for anti-cancer therapeutics. In the present study, we evaluated the effects of TMPyP4 on the proliferation and apoptosis of human cervical cancer cells and further explored its underlying mechanisms.
Human cervical cancer cell line Hela and human normal cervical cells (Academia Sinica Cell Bank, Shanghai, China) were grown in low-glucose Dulbecco’s modified Eagle medium (GibcoBRL, Grand Island, NY, USA) supplemented with 10% (v/v) fetal bovine serum (Sigma-Aldrich Chemicals, USA), 100 IU/mL penicillin, and 10 mg/mL streptomycin. Cells were cultured in a incubator with 5% CO2 at 37 °C.
Cell viability assay
Cell viability was assessed using MTT assay (Bestbio Biotechnology, Shanghai, China). Briefly, fresh human cervical cancer cells and human normal cervical cells at a concentration of 5 × 103 cells/well were seeded in 96-well flat-bottomed tissue culture plates (Corning Inc., Corning, NY, USA) with complete culture medium and incubated for 24 h. Following two washes with phosphate-buffered saline (PBS), cells were incubated in 100 μL culture medium containing 1, 5, 10 or 20 μM TMPyP4 for 24 h at 37 °C prior to the MTT assay. Then, a total of 10 μL MTT and 100 μL culture medium was added to each well, and incubated for 1 h at 37 °C. The optical densities of the samples were measured directly using a spectrophotometric microplate reader (Beyotime Institute of Biotechnology, Haimen, China) at a wavelength of 490 nm. Each experiment was performed in triplicate and repeated six times.
Cell apoptosis assay
The apoptotic cells were identified by FCM according to the published article . Human cervical cancer cells and human normal cervical cells at a density of 2 × 104/mL were cultured in 10% FBS-containing DMEM with 1, 5, 10 or 20 μM TMPyP4 for 24 h, respectively. Cells were harvested and washed twice with cold PBS by gentle shaking. Resuspended cells were added to 1× binding buffer and cell density was adjusted to 200,000–500,000/mL. In the dark, 5 μL of Annexin V-FITC (50 mM TRIS, 100 mM NaCl, 1% BSA, 0.02% sodium azide, pH 7.4) was added to the cell suspension in a mix of 195 μL and incubated for 10 min at room temperature before adding 190 μL 1× binding buffer and 10 μL propidium iodide (PI). Cell apoptosis was assayed using a FACScan flow cytometry apparatus (BD Biosciences, San Jose, CA, USA) and the percentage of apoptotic cells was analyzed using FlowJo 7.6.1 software (TreeStar, Inc., Ashland, OR, USA). Each experiment was performed in triplicate and repeated six times.
Western blot analysis
Following the treatment with 20 μM TMPyP4 for 24 h, cells were collected for protein extraction. The examination of the expression levels of caspase-3, MK-2, PARP, p38 MAPK and p-p38 MAPK was then performed. Total protein was extracted and the bicinchoninic acid assay kit (Beyotime Institute of Biotechnology) was used to measure the protein concentration. A total of 20 μg protein was separated by SDS-PAGE and transferred onto a polyvinylidene fluoride membrane using wet transfer apparatus (Bio-Rad, Hercules, CA, USA). The membranes were then blocked with 5% skimmed milk and incubated overnight at 4 °C with the primary antibodies, followed by incubation with the secondary antibodies labeled with HRP. Next, the protein bands were visualized using an enhanced chemiluminescence kit (Millipore, Billerica, MA, USA) and the protein levels were detected using the chemiluminescence reader, ImageQuant™ LAS4000 (GE Healthcare, Pittsburgh, PA, USA). Antibodies were purchased from Santa Cruz Biotechnology, CA, USA. Band density was quantitated using Image J software (Image J 1.35, National Institute of Mental Health, USA).
Caspase-3 activity assay
Caspase-3 activity was analyzed using caspase-3 activity assay kits according to the manufacturer’s instructions. Briefly, the reaction buffer and the specific enzyme DEVD-pNA were added to each cell plate and further cultured in an incubator for 1 h at 37 °C. The developed colorimetric reaction was measured at 405 nm in a 96-well Biorad 680 microplate reader (Bio-Rad, Hercules, CA, USA).
Block of p38 MAPK signaling using inhibitor
Cells were treated with p38 MAPK inhibitor SB203580 (5 μM) for 24 h followed by addition of 20 μM TMPyP4, and further incubated for 24 h. Then, cell proliferation and apoptosis were evaluated.
All results were analyzed using SPSS 17.0 statistical software (IBM, Armonk, NY, USA). Data are presented as the mean ± standard deviation (SD). Student’s two-tailed t test was used to determine the statistical differences between the treatment and control groups. P values were based on the two sided statistical analysis, and P < 0.05 was considered to indicate a statistically significant difference.
TMPyP4 inhibited the proliferation rates of human cervical cancer cells
TMPyP4 induced the apoptosis of human cervical cancer cells
TMPyP4 activated p38 MAPK signaling in human cervical cancer cells
Activation of p38 MAPK signaling in human cervical cancer cells is required for TMPyP4-induced down-regulation of cell viability
Activation of p38 MAPK signaling in human cervical cancer cells is required for TMPyP4-triggered apoptosis
TMPyP4, serving as a photosensitizer in PDT, has proved to play an essential role in controlling osteosarcoma . Besides, TMPyP4 has been recently developed as a chemotherapeutics drug to inhibit telomerase activity through binding to and stabilizing telomeric G-quadruplex DNA in cancer cells [7–9]. Through directly interaction with telomeres, TMPyP4 can rapidly evoke antiproliferative effects . In vivo, after intratumor injection of 10 mg/kg TMPyP4 for 10 days, cervical tumor growth in nude mice was significantly inhibited without any injury to the skin and internal organs . Therefore, in this study, we used this agent for investigation in cultured human cervical cancer cells to further evaluate its antitumor effects and underlying mechanism.
In the present study, treatment with various concentration of TMPyP4 significantly induced inhibition of proliferation in human cervical cancer cells. Previous report suggested that TMPyP4 could lead to progressive telomere shortening that eventually resulted in cancer cell apoptosis . Mikami-Terao et al. ever demonstrated that treatment with 100 μM TMPyP4 significantly inhibited the growth of K562 leukemic cells, with decreases of cells in the G(1) phase and increases of those in the S and G(2)/M phases after 48 h . In the following study, Mikami-Terao and his team found that TMPyP4 at doses of 10, 20, 50 or 100 μM significantly inhibited the growth of retinoblastoma cell lines, Y79 and WERI-Rb1 cells. In contrast, cell apoptosis was induced by TMPyP4 in a dose-dependent manner in both cell lines, which was associated with the increased expression of phosphorylated p53 (Ser46) protein and activation of MAPK . TMPyP4 at concentrations of 3, 6, 15, 30 or 60 μM significantly inhibited the proliferation and motility of human ovarian carcinoma A2780 cells but suppressed the expression levels of minichromosome maintenance protein-2 (MCM2) and carbonic anhydrase IX (CA-IX) . Additionally, TMPyP4 inhibited proliferation while induced apoptosis in colon cancer cells SW480 by the suppression of Wnt/β-catenin signaling pathway . More recently, a study demonstrated that, TMPyP4 at low doses less than 0.5 μM could promote the migration of human lung cancer A549 cells, HeLa, osteosarcoma U2OS and SAOS2. In contrast, TMPyP4 at high-dose larger than 2 μM inhibited cell proliferation and induced cell apoptosis in these cells . These findings above provided new insights into TMPyP4 which could be developed as a possible anticancer drug.
Numerous studies have indicated that the mitogen-activated protein kinase (MAPK) signaling pathway plays an important role in regulating cell proliferation, promoting cell cycle progression [19–21], and inducing resistance to radiotherapy and chemotherapy in tumor cells [22, 23]. In addition, p38 MAPK signaling cascade is a major pathway participating in the apoptotic pathway to suppress apoptosis of tumor cells [24, 25]. For instance, K562 leukemic cells treated with 100 μM TMPyP4 showed a decrease in c-Myc protein expression, and an obvious increase in the expression of p21 (CIP1), p57 (KIP2), p38 MAPK, c-Jun N-terminal kinase, and extracellular signal-regulated kinase . Most interestingly, our data showed that TMPyP4 could promote the expression level of p-p38 MAPK in human cervical cancer cells, implicating p38 MAPK activation as a potential target for TMPyP4. Also, we provided the evidence that the p38 MAPK signaling was involved in TMPyP4-indcued changes in proliferation and apoptosis of human cervical cancer cells.
In conclusion, we not only revealed a critical role for TMPyP4 in human cervical cancer cell proliferation and apoptosis, but also explored the molecular mechanisms by which TMPyP4 contributed to its antitumor effects. Up-regulation of the p38 MAPK signaling pathway by TMPyP4 could inhibit cell proliferation while promoted cell apoptosis in human cervical cancer cells. This study provided insight into the molecular mechanism of the antitumor effects of TMPyP4, indicating the p38 MAPK signaling might be a potential therapeutic target for TMPyP4 in human cervical cancer.
CYG was the guarantor of integrity of the entire study and was responsible for manuscript review. CMJ designed this study and took experimental studies. Both authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
This work was supported by Shanghai Medical Specialty Construction Project (ZK2015B08) and Project of Jiading District Health Bureau of Shanghai (WS201607).
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC. Human papillomavirus and cervical cancer. Lancet. 2013;382:889–99.View ArticlePubMedGoogle Scholar
- Campos NG, Sharma M, Clark A, Kim JJ, Resch SC. Resources required for cervical cancer prevention in low- and middle-income countries. PLoS ONE. 2016;11(10):e0164000.View ArticlePubMedPubMed CentralGoogle Scholar
- Arbyn M, Castellsagué X, de Sanjosé S, Bruni L, Saraiya M, Bray F. Worldwide burden of cervical cancer in 2008. Ann Oncol. 2011;22(12):2675–86.View ArticlePubMedGoogle Scholar
- Kodama J, Seki N, Masahiro S, Kusumoto T, Nakamura K, Hongo A, Hiramatsu Y. Prognostic factors in stage IB–IIB cervical adenocarcinoma patients treated with radical hysterectomy and pelvic lymphadenectomy. J Surg Oncol. 2010;101:413–7.PubMedGoogle Scholar
- Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.View ArticlePubMedGoogle Scholar
- Fujimori J, Matsuo T, Shimose S, Kubo T, Ishikawa M, Yasunaga Y, Ochi M. Antitumor effects of telomerase inhibitor TMPyP4 in osteosarcoma cell lines. J Orthop Res. 2011;29:1707–11.View ArticlePubMedGoogle Scholar
- Grand CL, Han H, Muñoz RM, Weitman S, Von Hoff DD, Hurley LH, Bearss DJ. The cationic porphyrin TMPyP4 down-regulates c-MYC and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo. Mol Cancer Ther. 2002;1:565–73.PubMedGoogle Scholar
- Rha SY, Izbicka E, Lawrence R, Davidson K, Sun D, Moyer MP, Roodman GD, Hurley L, Von Hoff D. Effect of telomere and telomerase interactive agents on human tumor and normal cell lines. Clin Cancer Res. 2000;6(3):987–93.PubMedGoogle Scholar
- Shammas MA, Shmookler Reis RJ, Akiyama M, Koley H, Chauhan D, Hideshima T, Goyal RK, Hurley LH, Anderson KC, Munshi NC. Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma. Mol Cancer Ther. 2003;2(9):825–33.PubMedGoogle Scholar
- Xia ZX, Li ZX, Zhang M, Sun LM, Zhang QF, Qiu XS. CARMA3 regulates the invasion, migration, and apoptosis of non-small cell lung cancer cells by activating NF-кB and suppressing the P38 MAPK signaling pathway. Exp Mol Pathol. 2016;100(2):353–60.View ArticlePubMedGoogle Scholar
- Mergny JL, Hélène C. G-quadruplex DNA: a target for drug design. Nat Med. 1998;4(12):1366–7.View ArticlePubMedGoogle Scholar
- Izbicka E, Wheelhouse RT, Raymond E, Davidson KK, Lawrence RA, Sun D, Windle BE, Hurley LH, Von Hoff DD. Effects of cationic porphyrins as G-quadruplex interactive agents in human tumor cells. Cancer Res. 1999;59(3):639–44.PubMedGoogle Scholar
- Liu AH, Sun X, Wei XQ, Zhang YZ. Efficacy of multiple low-dose photodynamic TMPYP4 therapy on cervical cancer tumour growth in nude mice. Asian Pac J Cancer Prev. 2013;14(9):5371–4.View ArticlePubMedGoogle Scholar
- Mikami-Terao Y, Akiyama M, Yuza Y, Yanagisawa T, Yamada O, Yamada H. Antitumor activity of G-quadruplex-interactive agent TMPyP4 in K562 leukemic cells. Cancer Lett. 2008;261(2):226–34.View ArticlePubMedGoogle Scholar
- Mikami-Terao Y, Akiyama M, Yuza Y, Yanagisawa T, Yamada O, Kawano T, Agawa M, Ida H, Yamada H. Antitumor activity of TMPyP4 interacting G-quadruplex in retinoblastoma cell lines. Exp Eye Res. 2009;89(2):200–8.View ArticlePubMedGoogle Scholar
- Liu H, Lv C, Ding B, Wang J, Li S, Zhang Y. Antitumor activity of G-quadruplex-interactive agent TMPyP4 with photodynamic therapy in ovarian carcinoma cells. Oncol Lett. 2014;8(1):409–13.PubMedPubMed CentralGoogle Scholar
- Zhang YQ, Zhang YH, Xie J, Li MN, Liu ZR, Shen JY, Shi SS, Lan XY, Wang S, Cheng NL. TMPyP4-regulated cell proliferation and apoptosis through the Wnt/β-catenin signaling pathway in SW480 cells. J Recept Signal Transduct Res. 2016;36(2):167–72.View ArticlePubMedGoogle Scholar
- Zheng XH, Nie X, Liu HY, Fang YM, Zhao Y, Xia LX. TMPyP4 promotes cancer cell migration at low doses, but induces cell death at high doses. Sci Rep. 2016;6:26592.View ArticlePubMedPubMed CentralGoogle Scholar
- Browne AJ, Göbel A, Thiele S, Hofbauer LC, Rauner M, Rachner TD. p38 MAPK regulates the Wnt inhibitor Dickkopf-1 in osteotropic prostate cancer cells. Cell Death Dis. 2016;7:e2119.View ArticlePubMedPubMed CentralGoogle Scholar
- Lin Y, Mallen-St Clair J, Wang G, Luo J, Palma-Diaz F, Lai C, Elashoff DA, Sharma S, Dubinett SM, St John M. p38 MAPK mediates epithelial–mesenchymal transition by regulating p38IP and snail in head and neck squamous cell carcinoma. Oral Oncol. 2016;60:81–9.View ArticlePubMedGoogle Scholar
- Zhang C, Shi J, Mao SY, Xu YS, Zhang D, Feng LY, Zhang B, Yan YY, Wang SC, Pan JP, Yang YP, Lin NM. Role of p38 MAPK in enhanced human cancer cells killing by the combination of aspirin and ABT-737. J Cell Mol Med. 2015;19(2):408–17.View ArticlePubMedGoogle Scholar
- Liu CL, Chen SF, Wu MZ, Jao SW, Lin YS, Yang CY, Lee TY, Wen LW, Lan GL, Nieh S. The molecular and clinical verification of therapeutic resistance via the p38 MAPK-Hsp27 axis in lung cancer. Oncotarget. 2016;7(12):14279–90.PubMedPubMed CentralGoogle Scholar
- Park SH, Seong MA, Lee HY. p38 MAPK-induced MDM2 degradation confers paclitaxel resistance through p53-mediated regulation of EGFR in human lung cancer cells. Oncotarget. 2016;7(7):8184–99.PubMedPubMed CentralGoogle Scholar
- Hui K, Yang Y, Shi K, Luo H, Duan J, An J, Wu P, Ci Y, Shi L, Xu C. The p38 MAPK-regulated PKD1/CREB/Bcl-2 pathway contributes to selenite-induced colorectal cancer cell apoptosis in vitro and in vivo. Cancer Lett. 2014;354(1):189–99.View ArticlePubMedGoogle Scholar
- Martin-Blanco E. p38 MAPK signalling cascades: ancient roles and new functions. BioEssays. 2000;22:637–45.View ArticlePubMedGoogle Scholar